Zoetis' Cytopoint Plus Gets USDA License for 75-Day Canine Itch Relief
Zoetis Receives USDA License for Cytopoint Plus™: The First and Only Long-Acting Monoclonal Antibody Providing 75 Days of Allergic Itch Relief in Dogs with Allergic Dermatitis
What Are Wall Street Analysts' Target Price for Zoetis Stock?
Should You Buy Zoetis Stock At This Price?
Zoetis to Participate in the Jefferies Global Healthcare Conference in London
ZTS Q3 2026 deep dive: competitive pressures and margin headwinds weigh on outlook
ZTS Q3 Earnings Call Highlights Competitive Pressures and Outlook
What Zoetis (ZTS) Said on Its Q3 Earnings Call
Zoetis (ZTS) Stock Price Drops After Q3 Earnings Margin Pressure
Zoetis: Quality Company Trading Cheap
Zoetis Inc. (ZTS) Q3 2026 Earnings Call Transcript
Zoetis: 3 Key Takeaways for Long-Term Investors
Zoetis Inc. 2026 Q3 - Results - Earnings Call Presentation
Zoetis (ZTS) Q3 2026 Earnings Call Transcript
Zoetis Inc. Reports Third Quarter 2026 Results and Updates Full Year 2026 Guidance
ZTS Q3 Earnings Top Estimates, 2026 Profit Outlook Improves, Stock Up
No Greyhounds Here: Pet-Health Giant Zoetis Reverses 30% Monthlong Sprint
Zoetis Lifts Annual Outlook While Braces For Cautious Pet Economy
Zoetis Adds To 21% Monthlong Run, Barking Up A Third-Quarter Beat
Zoetis (ZTS) Reports Q3 Earnings: What Key Metrics Have to Say
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.